803 related articles for article (PubMed ID: 21956718)
41. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.
Mashiko T; Sakashita E; Kasashima K; Tominaga K; Kuroiwa K; Nozaki Y; Matsuura T; Hamamoto T; Endo H
J Biol Chem; 2016 Jul; 291(29):14996-5007. PubMed ID: 27226551
[TBL] [Abstract][Full Text] [Related]
42. Neurotrophic effects of progranulin in vivo in reversing motor neuron defects caused by over or under expression of TDP-43 or FUS.
Chitramuthu BP; Kay DG; Bateman A; Bennett HP
PLoS One; 2017; 12(3):e0174784. PubMed ID: 28358904
[TBL] [Abstract][Full Text] [Related]
43. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
[No Abstract] [Full Text] [Related]
44. TDP-43/FUS in motor neuron disease: Complexity and challenges.
Guerrero EN; Wang H; Mitra J; Hegde PM; Stowell SE; Liachko NF; Kraemer BC; Garruto RM; Rao KS; Hegde ML
Prog Neurobiol; 2016; 145-146():78-97. PubMed ID: 27693252
[TBL] [Abstract][Full Text] [Related]
45. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
47. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.
Tyzack GE; Luisier R; Taha DM; Neeves J; Modic M; Mitchell JS; Meyer I; Greensmith L; Newcombe J; Ule J; Luscombe NM; Patani R
Brain; 2019 Sep; 142(9):2572-2580. PubMed ID: 31368485
[TBL] [Abstract][Full Text] [Related]
48. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration.
Fiesel FC; Kahle PJ
FEBS J; 2011 Oct; 278(19):3550-68. PubMed ID: 21777389
[TBL] [Abstract][Full Text] [Related]
49. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.
Lagier-Tourenne C; Polymenidou M; Cleveland DW
Hum Mol Genet; 2010 Apr; 19(R1):R46-64. PubMed ID: 20400460
[TBL] [Abstract][Full Text] [Related]
50. ALS and FTLD: two faces of TDP-43 proteinopathy.
Liscic RM; Grinberg LT; Zidar J; Gitcho MA; Cairns NJ
Eur J Neurol; 2008 Aug; 15(8):772-80. PubMed ID: 18684309
[TBL] [Abstract][Full Text] [Related]
51. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
[TBL] [Abstract][Full Text] [Related]
52. ALS-Related Mutant FUS Protein Is Mislocalized to Cytoplasm and Is Recruited into Stress Granules of Fibroblasts from Asymptomatic FUS P525L Mutation Carriers.
Lo Bello M; Di Fini F; Notaro A; Spataro R; Conforti FL; La Bella V
Neurodegener Dis; 2017; 17(6):292-303. PubMed ID: 29035885
[TBL] [Abstract][Full Text] [Related]
53. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
[TBL] [Abstract][Full Text] [Related]
54. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis.
Broustal O; Camuzat A; Guillot-Noël L; Guy N; Millecamps S; Deffond D; Lacomblez L; Golfier V; Hannequin D; Salachas F; Camu W; Didic M; Dubois B; Meininger V; Le Ber I; Brice A;
J Alzheimers Dis; 2010; 22(3):765-9. PubMed ID: 21158017
[TBL] [Abstract][Full Text] [Related]
55. Misregulated RNA processing in amyotrophic lateral sclerosis.
Polymenidou M; Lagier-Tourenne C; Hutt KR; Bennett CF; Cleveland DW; Yeo GW
Brain Res; 2012 Jun; 1462():3-15. PubMed ID: 22444279
[TBL] [Abstract][Full Text] [Related]
56. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
[TBL] [Abstract][Full Text] [Related]
57. ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity.
An H; Litscher G; Watanabe N; Wei W; Hashimoto T; Iwatsubo T; Buchman VL; Shelkovnikova TA
Neurobiol Dis; 2022 Jan; 162():105585. PubMed ID: 34915152
[TBL] [Abstract][Full Text] [Related]
58. Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS.
Motaln H; Čerček U; Yamoah A; Tripathi P; Aronica E; Goswami A; Rogelj B
Brain; 2023 Oct; 146(10):4088-4104. PubMed ID: 37071594
[TBL] [Abstract][Full Text] [Related]
59. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
Prudlo J
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
[TBL] [Abstract][Full Text] [Related]
60. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.
Ince PG; Highley JR; Kirby J; Wharton SB; Takahashi H; Strong MJ; Shaw PJ
Acta Neuropathol; 2011 Dec; 122(6):657-71. PubMed ID: 22105541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
